Although the anti PD-1 Nivolumab was recently approved to treat advanced (metastatic) clear cell renal cell carcinoma (ccRCC), only a minority of patients display a durable anti PD-1 response. The gene discussed is PDCD1; the disease is nonpapillary renal cell carcinoma.